Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Mesoblast (MESO) announced that it has entered into the Medicaid National Drug Rebate Agreement, NDRA, with the U.S. Centers for Medicare & ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative”, "BRTX” or the "Company”) ...

TFE3 fusion proteins are the oncogenic drivers of translocation renal cell carcinoma but their mechanism of action remains ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil® (remestemcel-L) the first mesenchymal stromal cell ...

Currently, there are only two cell and gene therapies (CGTs) on the market across all gastroenterology (GI) indications. Anterogen's Cupistem, indicated for the treatment of anal fistula in adult ...

A new discovery has shed new light on the crucial role of the CD47 protein in bone fracture healing. Scientists have ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing product development New tagline to emphasize the company’s ...

Nature Cell Co. Ltd. won U.S. FDA breakthrough therapy designation of its autologous adipose-derived mesenchymal stem cell therapy, Jointstem, March 20, becoming the first Korean company to earn the ...